Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in... see more

Add To Watchlist

Recent & Breaking News (TSXV:BTI.H)

biOasis Announces the Successful Delivery to the CNS of an Enzyme Used to Treat Hunter Syndrome

Marketwired July 31, 2015

biOasis Technologies Inc. and Brigham and Women's Hospital Inc., Enter a Neuro-Oncology Research & Collaboration Agreement

Marketwired July 21, 2015

biOasis Technologies Inc. and Brigham and Women's Hospital Inc., Enter a Neuro-Oncology Research & Collaboration Agreement

Marketwired July 21, 2015

biOasis Engages Kilmer Lucas for Cross-Border Investor Relations

Marketwired June 8, 2015

biOasis Enters Into A Collaborative Research and Joint Funding Support Agreement Entitled "Focus on Brain"

Marketwired May 27, 2015

biOasis Provides Scientific Updates on Its Transcend Programs

Marketwired May 12, 2015

biOasis European Patent Granted for The Use of Transcend for the Delivery of Enzymes to Treat Lysosomal Storage Disease in The Brain

Marketwired April 21, 2015

biOasis Releases Results From an Ischemic Stroke Model with Transcend BBB Carrier Peptide (MTfp):MTfp-siRNA Reduces Both the Damage Caused by Infarct and Significantly Improves Neurological Score

Marketwired March 16, 2015

biOasis Announces Grant of Stock Options

Marketwired January 30, 2015

biOasis Announces the Release of an Analyst Report

Marketwired January 20, 2015

biOasis Engages Willow Tree Group to Assist with Global Business Development Activities

Marketwired October 7, 2014

biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation

Marketwired September 18, 2014

biOasis Advances Its Lysosomal Storage Disease Program with a Knockout Model for Sandhoff Disease

Marketwired September 9, 2014

biOasis Announces NSERC Grant to the University of British Columbia in Support of Collaborative R&D Work with biOasis

Marketwired September 4, 2014

biOasis Closes Non-Brokered Private Placement for $1,609,753.15 Gross Proceeds

Marketwired August 29, 2014

WSA Talks to Two Dual-Listed Companies Making Waves

Marketwired August 21, 2014

biOasis Announces Non-Brokered Private Placement

Marketwired August 8, 2014

biOasis Releases Quantitative Results: siRNA-Transcendpep Reduces Target Gene Expression in the Brain

Marketwired July 25, 2014

biOasis Appoints New Chief Financial Officer and Corporate Secretary

Marketwired June 20, 2014

biOasis Enters Investor Relations Agreement with Gale Capital Corporation

Marketwired June 16, 2014